| Not Yet Recruiting | Low-level Laser Therapy on Oral Pemphigus Vulgaris Patients. NCT06971172 | Cairo University | N/A |
| Completed | Effect of Topical Insulin on Healing Rate of Pemphigus Lesions NCT07461103 | Alexandria University | Phase 2 |
| Recruiting | Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell NCT06581562 | IRIS Research and Development, LLC | Phase 1 |
| Unknown | Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid NCT05594472 | Cairo University | Phase 3 |
| Unknown | Role of Tzanck Smear in Determining Pemphigus Vulgaris Disease Activity NCT05338112 | Istanbul Medeniyet University | — |
| Completed | Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients NCT06167408 | First Affiliated Hospital of Chongqing Medical University | — |
| Recruiting | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Init NCT05635266 | Sanguine Biosciences | — |
| Terminated | COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders NCT05000216 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Terminated | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in A NCT04598477 | argenx | Phase 3 |
| Unknown | Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients NCT04096222 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | — |
| Completed | Comparing DCP and DAP for Pemphigus Vulgaris NCT06846255 | Jinnah Postgraduate Medical Centre | Phase 4 |
| Unknown | A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV) NCT05303272 | Tongji Hospital | Phase 4 |
| Completed | Dexamethasone Solution and Dexamethasone in Mucolox™ NCT04540133 | University of California, San Francisco | Phase 2 |
| Completed | A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With NCT04598451 | argenx | Phase 3 |
| Recruiting | A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody NCT04422912 | Cabaletta Bio | Phase 1 / Phase 2 |
| Unknown | Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus Vulgaris NCT04023149 | Second Xiangya Hospital of Central South University | Phase 2 |
| Unknown | Phenotypic and Functional Characterisation of Human B-cell Response in Pemphigus NCT04117529 | Assistance Publique - Hôpitaux de Paris | N/A |
| Withdrawn | A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris NCT03780166 | Incyte Corporation | Phase 2 |
| Completed | A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus NCT03334058 | argenx | Phase 2 |
| Terminated | Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus NCT03239470 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Terminated | A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) NCT03075904 | Alexion Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Unknown | Serum IL-21 Levels in Patients With Pemphigus Vulgaris NCT03177213 | Assiut University | — |
| Recruiting | Autoimmune Blistering Diseases Study NCT02753777 | University of Pennsylvania | — |
| Completed | A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris NCT02704429 | Principia Biopharma, a Sanofi Company | Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants Wi NCT02383589 | Hoffmann-La Roche | Phase 3 |
| Terminated | Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris NCT01930175 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris NCT01920477 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone NCT00626678 | Tehran University of Medical Sciences | Phase 2 |
| Completed | Use of KC706 for the Treatment of Pemphigus Vulgaris NCT00606749 | Kemia, Inc | Phase 2 |
| Terminated | Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus NCT00483119 | NYU Langone Health | Phase 2 |
| Completed | Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris NCT00135720 | Massachusetts General Hospital | Phase 2 |
| Completed | Safety Study of PI-0824 to Treat Pemphigus Vulgaris NCT00063752 | Peptimmune | Phase 1 |
| Terminated | Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris NCT00429533 | Jacobus Pharmaceutical | Phase 2 |